Proteomic-based integrated subject-specific networks in cancer

Slides:



Advertisements
Similar presentations
Internship Site #1 BioDiscovery Lead mentor: Bruce Hoff, Ph.D. Students will use BioDiscovery’s software tools to analyze gene or protein microarray data.
Advertisements

Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Reported by R5 李霖昆 Supervised by 楊慕華 大夫 Genomics-Driven Oncology: Framework for an Emerging Paradigm Review article Journal of Clinical Oncology 31, 15,
Computational characterization of biomolecular networks in physiology and disease Kakajan Komurov, Ph.D Department of Systems Biology University of Texas.
The Golden Age of Biology DNA -> RNA -> Proteins -> Metabolites Genomics Technologies MECHANISMS OF LIFE Health Care Diagnostics Medicines Animal Products.
Scientific Data Mining: Emerging Developments and Challenges F. Seillier-Moiseiwitsch Bioinformatics Research Center Department of Mathematics and Statistics.
Andrey Alexeyenko M edical E pidemiology and B iostatistics Gene network approach in epidemiology.
Sarcoma Research Laboratory University of Texas, MD Anderson Cancer Center Radiation-associated and sporadic UPS/MFH: Searching for novel therapeutic strategies.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Karl Clauser Proteomics and Biomarker Discovery Breast Cancer Proteomics and the use of TCGA Mutational Data - Broad Institute update/issues Karl Clauser.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best.
Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.
GeWorkbench Overview Support Team Molecular Analysis Tools Knowledge Center Columbia University and The Broad Institute of MIT and Harvard.
CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
Virginia G. Piper Center for Personalized Diagnostics Chromosome 10 Joshua LaBaer, M.D., Ph.D. Konstantinos Petritis, Ph.D. Virginia G. Piper Center for.
To develop the scientific evidence base that will lessen the burden of cancer in the United States and around the world. NCI Mission Key message:
Marc Berg Experience Relevant Publications
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
OMICS Journals are welcoming Submissions
Sungkyunkwan University, School of Medicine.
Szilard Voros, MD, FACC, FSCCT, FAHA Chief Executive Officer | Founder
A graph-based integration of multiple layers of cancer genomics data (Progress Report) Do Kyoon Kim 1.
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
The Immune System: Cancer
Proteomic analysis reveals Src/Stat and EGFR/MAPK pathways as potential mechanism of resistance to PI3K inhibitors in lung cancer Maria Angelica Cortez1,
Cancer Genomics and Class Discovery
A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716
Clinical evaluation of UHC for cancer
Optimizing Biological Data Integration
Songjian Lu, PhD Assistant Professor
Interrogation of cross talk between proteins and gene regulatory networks in breast cancer Chambers, Teressa Lee Hiren Karathia Sridhar Hannenhalli.
Global Transcriptional Dysregulation in Breast Cancer
Stem Cell Research
Biostatistics?.
ATOM Accelerating Therapeutics for Opportunities in Medicine
Connecting Cancer Genomics to Cancer Biology using Proteomics
A Functional Map of Oncogenic States for Breast Cancer
Metastatic HER2+ Breast Cancer: Resistance
Dept of Biomedical Informatics University of Pittsburgh
Knowledge l Action l Impact
Songjian Lu, PhD Assistant Professor
Breast Cancer By:Nina Bullock.
Nat. Rev. Urol. doi: /nrurol
The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome  Alexandria D. Taylor,
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
“Stem Cells and Cancer”
From Data to Therapies Research in Xinghua Lu’s Lab
Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.
Figure 1 A schematic representation of the HER2 signalling pathway
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
BIOLOGY 12 Cancer.
Nat. Rev. Urol. doi: /nrurol
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
Volume 72, Issue 4, Pages (October 2017)
Volume 31, Issue 2, Pages (February 2017)
Nat. Rev. Urol. doi: /nrurol
Volume 3, Issue 4, Pages (April 2003)
Volume 58, Issue 4, Pages (May 2015)
Department of Biochemistry and Molecular Biology
Research Support Network (RAI)
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
Cell Cycle.
Specific Tumor Suppressor Genes
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.
Volume 3, Issue 4, Pages (April 2003)
No Driver behind the Wheel? Targeting Transcription in Cancer
Presentation transcript:

Proteomic-based integrated subject-specific networks in cancer Min Jin Ha Department of Biostatistics University of Texas MD Anderson Cancer Center

TEAM Key Personnel Min Jin Ha (PI) – Department of Biostatistics, UT MD Anderson Cancer Center Veerabhadran Baladandayuthapani (Co-PI) – Department of Biostatistics, UT MD Anderson Cancer Center Rehan Akbani (Co-I) – Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center Abishek Saha (post-doctoral fellow) – Department of Biostatistics, UT MD Anderson Cancer Center

Broad Objectives The cancer functional genome and proteome provides a rich source of information to identify patient-specific variations in signaling pathways and activities within and across tumor Patient-specific approaches have recently emerged, within a precision medicine paradigm, that acknowledges the fact that pathway structures and activity might be considerably different within and across tumor The overall objective is to develop general analytic frameworks to characterize patient-specific pathway signatures by sequential estimations of cancer-specific (global) and patient-specific (local) networks

ANALYTICAL Schema & Specific Aims

Data Resources Reverse-phase protein array (RPPA)-based proteomic data from The Cancer Genome Atlas (TCGA) across 33 cancer types and MD Anderson Cell Lines Project (MCLP) across 19 tumor lineages Dr. Akbani (Co-I) have led the generation and curation of these comprehensive databases The MDACC TCGA RPPA platform includes extensively validated 181 high- quality antibodies that target proteins covering major signaling pathways, including apoptosis, cell cycle, DNA damage, PI3K, MAPK and mTOR pathways

Breast cancer subtypes Of the patients with HER2-positive breast cancer in cluster C1,75% showed activation of the RTK pathway that includes HER2 (ERBB2) protein All patients in C3 had HER2-negative breast cancer 66%, 82%, and 72% of the patients in C3 showed activation of the apoptosis, breast reactive, and RAS/MAPK pathways, respectively

Higher prognostic power of PRECISE scores as compared to naïve/existing approaches

timeline Methods were developed and the application to TCGA data across 33 cancer types are under revision in Scientific Reports